Poster 51
- Kelley Tangredi
- May 15, 2023
- 1 min read
Updated: Jul 8, 2023
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Authors: Mark Lebwohl, Bruce Strober, Thomas Scharnitz, Misti Linaberry, Kim Hoyt, Subhashis Banerjee, Renata M. Kisa, George Martin

Commentaires